Targeting Multiple Myeloma with AMG 424, a Novel Anti-CD38/CD3 Bispecific T-cell–recruiting Antibody Optimized for Cytotoxicity and Cytokine Release
Clinical Cancer Research2019Vol. 25(13), pp. 3921–3933
Citations Over TimeTop 1% of 2019 papers
Christina L. Zuch de Zafra, Flordeliza Fajardo, Wendy Zhong, Matthew J. Bernett, Umesh S. Muchhal, Gregory L. Moore, Jennitte Stevens, Ryan Case, Joshua T. Pearson, Siyuan Liu, Patricia McElroy, Jude Canon, John R. Desjarlais, Angela Coxon, Mercedesz Balázs, Olivier Nolan-Stevaux
Abstract
These findings support the clinical development of AMG 424, an affinity-optimized T-cell-recruiting antibody with the potential to elicit significant clinical activity in patients with multiple myeloma.
Related Papers
- → Impaired Cytotoxic CD8 + T Cell Response in Elderly COVID-19 Patients(2020)151 cited
- → Antigen‐specific suppression of cytotoxic T cell responses in mice. I. Suppressor T cells are not cytotoxic cells(1978)40 cited
- → The “Triggering” of Cytotoxic Cell Differentiation in Secondary Cultures by Subcellular Antigens(1979)4 cited
- Orally induced tolerance.(1979)
- The cytotoxic activity of mouse T lymphocytes against allogeneic cytotoxic T cells.(1975)